Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tecadenoson. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 known ✓ | P30542 | 13/20 | 0.91 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.91 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.91 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.91 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.91 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.91 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.72 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | TP53 | P04637 | 1/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tecadenoson SCHEMBL1095647 | 0.95 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| Tecadenoson SCHEMBL12265126 | 0.95 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| Tecadenoson SCHEMBL6226634 | 0.95 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| Tecadenoson SCHEMBL15106884 | 0.95 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| Tecadenoson SCHEMBL472549 | 0.95 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| Tecadenoson SCHEMBL24838611 | 0.95 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| Tecadenoson SCHEMBL246787 | 0.95 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| Tecadenoson SCHEMBL472425 | 0.95 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| Tecadenoson SCHEMBL22349437 | 0.95 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| Tecadenoson SCHEMBL7034923 | 0.95 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2412716-A1 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. (US) | 2012-02-01 | — | — | EP | disclosed |
| US-7696181-B2 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090325896-A1 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | IBRAHIM PRABHA | 2009-12-31 | — | — | US | disclosed |
| US-20060287275-A1 | Partial and full agonists of A1 adenosine receptors | IBRAHIM PRABHA | 2006-12-21 | — | — | US | disclosed |
| US-7144871-B2 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1476455-A1 | PARTIAL AND FULL AGONISTS OF A sb 1 /sb ADENOSINE RECEPTORS | CV THERAPEUTICS, INC. (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20030232783-A1 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003070739-A1 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | CV THERAPEUTICS, INC. (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325896-A1 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | ADORA1, ADORA2A, ADORA3 | ADORA1 1/4885ADORA3 3/4885ADORA2A 2/4885 |
| US-20060287275-A1 | Partial and full agonists of A1 adenosine receptors | ADORA1, ADORA2A, ADORA3 | ADORA1 1/4885ADORA3 3/4885ADORA2A 2/4885 |
| US-20030232783-A1 | Partial and full agonists of A1 adenosine receptors | ADORA1, ADORA2A, ADORA3 | ADORA1 1/4885ADORA3 3/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.